Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

As Santech announced in its press release dated November 25, 2024, Santech received a deficiency letter from Nasdaq stating that Santech is not in compliance with the Rules because it has not yet ...

Group received notice from the Listing Qualifications Department of the Nasdaq Stock Market on February 5, indicating that the ...

On February 4, 2025, the Company filed the required Form 6-K to report its unaudited condensed consolidated statements of profit or loss and statements of financial position as of and for the quarter, ...

Strategy's share sales from its at-the-market offering were just below 3% of the total cumulative trading volume.

Etsy, Inc. (Nasdaq: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced that effective February 3, ...

Solid Biosciences (SLDB) announced grants of 31,101 restricted stock units to two newly hired employees. The RSUs vest in four equal ...

K SEC filing received on January 31, 2025, that the company has been notified by The Nasdaq Stock Market, LLC about its failure to meet the minimum bid requirement for continued listing on the Nasdaq ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...